AI Healthcare Showdowns — ChatGPT vs. Claude vs. Perplexity vs. Gemini
Head-to-head comparisons of major AI platforms for real healthcare scenarios — prescriptions, insurance, billing, diagnosis research, and patient advocacy.
Testing methodology: Each scenario was tested 3 times per platform using identical prompts. Scored on accuracy, actionability, source quality, safety disclaimers, and practical usefulness.
⚠️ Important: AI outputs are for research and preparation only — never substitute for medical advice from your healthcare team.
Showdown #1: "Find the Cheapest Way to Fill My Prescription"
Scenario: Patient takes Eliquis (apixaban) 5mg twice daily, has a high-deductible health plan, and pays $550/month out-of-pocket. Needs to find affordable options.
ChatGPT (GPT-4o) — Score: 8/10
Strengths:
Identified Cost Plus Drugs ($32/month) and GoodRx ($95/month from Costco) immediately
Suggested Bristol-Myers Squibb patient assistance program with income thresholds
Recommended asking doctor about dose optimization
Provided step-by-step instructions for each option
Weaknesses:
Prices were directionally correct but not real-time accurate
Didn't mention the manufacturer copay card (savings up to $6,400/year)
Missed Canadian pharmacy options (legal for personal use)
Claude — Score: 8.5/10
Strengths:
Most comprehensive list of savings options (7 different pathways)
Identified the manufacturer copay card AND patient assistance program
Explained the difference between copay cards (for insured patients) and PAP (for uninsured/underinsured)
Provided a decision tree: "If your income is below X, start with PAP. If above X with insurance, try the copay card first."
Weaknesses:
No real-time pricing (by design — Claude doesn't browse)
Slightly longer response required more reading
Perplexity — Score: 9/10 ⭐
Strengths:
Real-time pricing with links to GoodRx, Cost Plus, and pharmacy websites
Showed current prices at specific nearby pharmacies
Cited manufacturer's website directly for the copay card
Included a comparison table with actual current prices
Weaknesses:
Less detailed explanation of patient assistance program eligibility
Didn't provide the decision framework Claude offered
Gemini — Score: 7/10
Strengths:
Good overview of generic availability timeline (apixaban generic expected 2028)
Correctly identified Mark Cuban's Cost Plus Drugs
Adequate safety disclaimers
Weaknesses:
Missed the manufacturer copay card entirely
Less specific on pricing
Didn't suggest pharmacy comparison shopping
Winner: Perplexity 🏆
For prescription pricing, Perplexity's real-time web access is decisive. It gives you actual current prices you can act on today. Use Claude as a complement for strategy and decision-making.
Showdown #2: "Help Me Understand and Appeal This Insurance Denial"
Scenario: Insurance denied prior authorization for Ozempic (semaglutide) prescribed for Type 2 diabetes management. Denial reason: "step therapy required — must try metformin first." Patient has already tried metformin with documented side effects.
ChatGPT — Score: 8.5/10
Strengths:
Immediately identified this as a "step therapy override" situation
Drafted a strong appeal letter with correct medical terminology
Referenced ADA Standards of Care guidelines supporting GLP-1 use after metformin intolerance
Included specific language about metformin side effects constituting medical necessity
Weaknesses:
Appeal letter was good but generic — needed more personalization guidance
Exceptional appeal letter — detailed, personalized, with clinical citations
Referenced specific clinical guidelines (ADA 2024 Standards of Care, Section 9)
Explained the step therapy override process in detail
Provided a complete timeline of what to expect
Mentioned state step therapy reform laws (many states now have protections)
Suggested documenting the metformin side effects in a specific format
Included escalation path: internal appeal → external review → state insurance commissioner
Weaknesses:
Lengthy response — the thoroughness takes time to read
Perplexity — Score: 7.5/10
Strengths:
Linked to actual ADA guidelines and CMS resources
Good factual foundation with sources
Weaknesses:
Appeal letter was more template-like, less strategic
Didn't provide the nuanced step therapy override strategy Claude offered
Less guidance on the emotional/practical aspects of the appeal process
Gemini — Score: 7/10
Strengths:
Correctly identified the denial type
Reasonable appeal framework
Weaknesses:
Appeal letter was too generic
Missed the step therapy override angle
Didn't reference specific clinical guidelines
Less actionable overall
Winner: Claude 🏆
For insurance appeals, Claude's depth, clinical citation accuracy, and strategic thinking are unmatched. The appeal letter it generates is nearly ready to submit (with your doctor's review). This is a scenario where thoroughness beats speed.
Showdown #3: "Audit My Hospital Bill for Errors"
Scenario: Patient received a $14,200 bill for an outpatient knee arthroscopy. Itemized charges include facility fee ($7,500), surgeon fee ($3,200), anesthesia ($2,100), post-op recovery room ($800), and "miscellaneous supplies" ($600). Patient suspects overcharging.
ChatGPT — Score: 8/10
Strengths:
Flagged the "miscellaneous supplies" charge as vague and potentially inflated
Provided fair market price ranges for each component
Suggested requesting CPT codes for verification
Recommended comparing against Medicare fee schedule as a benchmark
Weaknesses:
Price ranges were broad (facility fee "typically $3,000-$8,000" — not very helpful)
Didn't suggest specific negotiation tactics
Claude — Score: 8.5/10
Strengths:
Most detailed analysis of each line item with specific red flags
Identified potential unbundling (charging separately for what should be one code)
Explained the difference between hospital outpatient vs. ambulatory surgery center pricing
Provided a negotiation script for calling the billing department
Suggested checking if any charges violate the Good Faith Estimate requirement
Weaknesses:
Couldn't provide real-time fair market data
Analysis was appropriately cautious rather than definitive
Perplexity — Score: 8.5/10
Strengths:
Sourced current fair market data from healthcare cost databases
Linked to FAIR Health consumer tool for price comparison
Showed actual benchmark pricing for the geographic area
Referenced the No Surprises Act and Good Faith Estimate requirements
Weaknesses:
Less strategic advice on how to negotiate
Presented data without the "what to do about it" framework
Gemini — Score: 7.5/10
Strengths:
Reasonable flag on the total being above average
Mentioned the hospital financial assistance obligation
Weaknesses:
Less granular line-item analysis
Didn't identify specific billing error patterns
Generic advice
Winner: Tie — Claude + Perplexity 🏆🏆
Use Perplexity to get real-time fair market pricing benchmarks, then use Claude to analyze the bill strategically and generate your negotiation approach. This combination is devastating for billing departments that count on patients not questioning charges.
Showdown #4: "Research My New Diagnosis"
Scenario: Patient just diagnosed with Hashimoto's thyroiditis. Wants to understand the condition, treatment options, lifestyle implications, and what questions to ask their endocrinologist.
ChatGPT — Score: 8.5/10
Strengths:
Clear, well-organized explanation of the autoimmune mechanism
Covered all standard treatment options (levothyroxine, monitoring approach, etc.)
Good section on lifestyle factors (selenium, gluten connection, stress management)
Provided 10 specific questions for the endocrinologist
Weaknesses:
Some lifestyle claims (gluten-free, supplements) presented without sufficient caveats about evidence quality
Could have distinguished better between well-supported and preliminary research
Claude — Score: 9/10 ⭐
Strengths:
Exceptional distinction between established science and emerging research
Clearly labeled what's "well-established" vs. "preliminary evidence" vs. "popular but unproven"
Most nuanced explanation of the autoimmune spectrum and antibody monitoring
Addressed the emotional/psychological aspects of autoimmune diagnosis
Provided both mainstream and integrative medicine perspectives with appropriate evidence ratings
Questions for the endocrinologist were more sophisticated and specific
Weaknesses:
Lengthy — could overwhelm a patient who just wants the basics
Doesn't provide sources in-line (by design)
Perplexity — Score: 8.5/10
Strengths:
Every claim linked to a source (medical journals, patient organizations, Mayo Clinic)
Easy to verify any specific claim
Included links to Hashimoto's patient communities and advocacy organizations
Current research cited with publication dates
Weaknesses:
Less nuanced about evidence quality — sources are provided but reader must evaluate them
Read more like a research report than patient education
Gemini — Score: 7.5/10
Strengths:
Good visual organization with clear sections
Accessible language
Correctly identified key monitoring parameters
Weaknesses:
Less depth on treatment decision-making
Didn't address the common patient concern about symptoms persisting despite "normal" lab values
Generic lifestyle advice not specific to Hashimoto's
Winner: Claude 🏆
For understanding a new diagnosis, Claude's evidence-grading and nuanced presentation are invaluable. It helps you become an informed patient without leading you down unproven treatment rabbit holes. Pair with Perplexity for source verification.
Showdown #5: "Help Me Choose a Medicare Plan"
Scenario: 65-year-old newly eligible for Medicare. Takes 3 medications (lisinopril, atorvastatin, metformin), sees 2 specialists (cardiologist, endocrinologist), and wants to understand Original Medicare vs. Medicare Advantage options.
ChatGPT — Score: 8/10
Strengths:
Clear comparison table of Original Medicare vs. Medicare Advantage
Correctly explained Parts A, B, C, D structure
Provided decision framework based on health needs
Good explanation of Medigap supplemental insurance
Weaknesses:
Couldn't check specific plan availability in the patient's area
Medication formulary comparison was theoretical, not actionable
Claude — Score: 8.5/10
Strengths:
Most thorough decision framework — weighted pros/cons for this specific patient's profile
Excellent analysis of how the 3 medications and 2 specialists influence the decision
Addressed the "what if my health changes" scenario that most people don't think about
Explained the Medigap enrollment penalty that catches many people off guard
Provided a year-one vs. year-five cost comparison model
Weaknesses:
Can't access Medicare Plan Finder data in real-time
Theoretical analysis needs to be validated against actual available plans
Perplexity — Score: 8/10
Strengths:
Linked to Medicare.gov Plan Finder tool
Cited current year plan comparison data
Included recent Medicare Advantage star ratings
Referenced state-specific SHIP (State Health Insurance Assistance Program) counselors
Weaknesses:
Less strategic about the long-term implications of the choice
Didn't explain the Medigap penalty
Presented options without the personalized decision guidance
Gemini — Score: 7/10
Strengths:
Adequate overview of Medicare options
Mentioned the importance of prescription drug coverage
Referenced Medicare.gov
Weaknesses:
Most surface-level analysis
Didn't factor in the patient's specific medications and specialists
Missed the Medigap enrollment window issue
Generic advice that could apply to anyone
Winner: Claude 🏆
Medicare decisions are complex and long-term. Claude's ability to model scenarios, flag gotchas (like the Medigap penalty), and provide personalized strategic analysis makes it the best primary tool. Supplement with Perplexity for real-time plan data and SHIP counselor information.